Biolyst › BFRIBiofrontera Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 17, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.
Cash runway is approximately 199.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Track BFRI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BFRI in the tracker
Recent history
Date Event Type Phase
September 14, 2026
8-K filed: Other event Filing
—
August 13, 2026
Quarterly results filed (8-K) Earnings
—
May 14, 2026
Quarterly results filed (8-K) Earnings
—
March 19, 2026
Quarterly results filed (8-K) Earnings
—
March 9, 2026
8-K filed: Reg FD disclosure Filing
—
February 26, 2026
8-K filed: Other event Filing
—
February 9, 2026
8-K filed: Reg FD disclosure Filing
—
January 13, 2026
Quarterly results filed (8-K) Earnings
—
January 7, 2026
8-K filed: Listing / standard notice Corporate
—
November 13, 2025
Quarterly results filed (8-K) Earnings
—
November 10, 2025
8-K filed: Other event Filing
—
November 7, 2025
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate
—
October 24, 2025
8-K filed: Material agreement, Acquisition completed, Other event Corporate
—
October 23, 2025
8-K filed: Reg FD disclosure Filing
—
September 3, 2025
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp Trial Milestone
Phase 3
August 22, 2025
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults Trial Milestone
Phase 2
August 13, 2025
Quarterly results filed (8-K) Earnings
—
August 11, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
July 1, 2025
8-K filed: Material agreement Corporate
—
June 30, 2025
8-K filed: Reg FD disclosure Filing
—
June 11, 2025
8-K filed: Other event Filing
—
June 3, 2025
8-K filed: Other event Filing
—
May 23, 2025
8-K filed: Listing / standard notice Corporate
—
May 15, 2025
Quarterly results filed (8-K) Earnings
—
May 14, 2025
8-K filed: Listing / standard notice Corporate
—
March 19, 2024
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.